# Barinthus Bio Reports Full Year 2025 Financial Results and Updates on Corporate Developments
Canonical URL: https://biopharmsignal.com/news/BRNS/barinthus-bio-reports-full-year-2025-financial-results-and-updates-on-corporate-developments
Ticker: BRNS
Company: Barinthus Biotherapeutics
Source: Barinthus Biotherapeutics
Published: 2026-03-13 12:00 EST
Original Source URL: https://investors.barinthusbio.com
## Summary

Proposed combination with Clywedog Therapeutics Inc. (“Clywedog”) to create a differentiated company focusing on clinical metabolic and autoimmune pipeline assets and to build on the Company’s base of high caliber institutional investors, expected to complete in the second quarter of 2026 Multiple

## Article Body
Proposed combination with Clywedog Therapeutics Inc. (“Clywedog”) to create a differentiated company focusing on clinical metabolic and autoimmune pipeline assets and to build on the Company’s base of high caliber institutional investors, expected to complete in the second quarter of 2026 Multiple
## Recent Company News
- 2026-04-30 11:30 EST — [Barinthus Bio Reports First Quarter 2026 Financial Results and Updates on Corporate Developments](https://biopharmsignal.com/news/BRNS/barinthus-bio-reports-first-quarter-2026-financial-results-and-updates-on-corporate-developments) — Source: Barinthus Biotherapeutics
- 2026-03-13 12:00 EST — [Barinthus Bio Reports Full Year 2025 Financial Results and Updates on Corporate Developments](https://biopharmsignal.com/news/BRNS/barinthus-bio-reports-full-year-2025-financial-results-and-updates-on-corporate-developments) — Source: Barinthus Biotherapeutics
- 2025-12-10 13:00 EST — [Barinthus Bio Announces Update on Phase 1 AVALON Clinical Trial of VTP-1000 for the Treatment of Celiac Disease](https://biopharmsignal.com/news/BRNS/barinthus-bio-announces-update-on-phase-1-avalon-clinical-trial-of-vtp-1000-for-the-treatment-of-celiac-disease) — Source: Barinthus Biotherapeutics
- 2025-11-07 12:30 EST — [Barinthus Bio Reports Third Quarter 2025 Financial Results and Updates on Corporate Developments](https://biopharmsignal.com/news/BRNS/barinthus-bio-reports-third-quarter-2025-financial-results-and-updates-on-corporate-developments) — Source: Barinthus Biotherapeutics
- 2025-09-30 12:01 EST — [Barinthus Biotherapeutics to Combine with Clywedog Therapeutics to Target Metabolic and Autoimmune Diseases](https://biopharmsignal.com/news/BRNS/barinthus-biotherapeutics-to-combine-with-clywedog-therapeutics-to-target-metabolic-and-autoimmune-diseases) — Source: Barinthus Biotherapeutics
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)